162 related articles for article (PubMed ID: 26729828)
1. Genetic predisposition resulting in sinusoidal obstruction syndrome in a patient with resected sigmoid cancer on adjuvant oxaliplatin.
Koo SX; Chan SH; Ngeow J
BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26729828
[TBL] [Abstract][Full Text] [Related]
2. Glutathione S-transferase M1-null genotype as risk factor for SOS in oxaliplatin-treated patients with metastatic colorectal cancer.
Vreuls CP; Olde Damink SW; Koek GH; Winstanley A; Wisse E; Cloots RH; van den Broek MA; Dejong CH; Bosman FT; Driessen A
Br J Cancer; 2013 Feb; 108(3):676-80. PubMed ID: 23287989
[TBL] [Abstract][Full Text] [Related]
3. [Sinusoidal obstruction syndrome induced by FOLFOX adjuvant chemotherapy].
Chaput U; Coriat R; Terris B; Brezault C; Chaussade S
Gastroenterol Clin Biol; 2008 Dec; 32(12):992-4. PubMed ID: 19019605
[No Abstract] [Full Text] [Related]
4. Chemotherapy-induced Sinusoidal Injury (CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis.
Stevenson HL; Prats MM; Sasatomi E
BMC Cancer; 2017 Jan; 17(1):35. PubMed ID: 28061766
[TBL] [Abstract][Full Text] [Related]
5. Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases.
van den Broek MA; Vreuls CP; Winstanley A; Jansen RL; van Bijnen AA; Dello SA; Bemelmans MH; Dejong CH; Driessen A; Olde Damink SW
Ann Surg Oncol; 2013 May; 20(5):1462-9. PubMed ID: 23463086
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin-induced increase in splenic volume; irreversible change after adjuvant FOLFOX.
Iwai T; Yamada T; Koizumi M; Shinji S; Yokoyama Y; Takahashi G; Takeda K; Hara K; Ohta K; Uchida E
J Surg Oncol; 2017 Dec; 116(7):947-953. PubMed ID: 28876454
[TBL] [Abstract][Full Text] [Related]
7. Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX.
Kim MJ; Han SW; Lee DW; Cha Y; Lee KH; Kim TY; Oh DY; Kim SH; Im SA; Bang YJ; Kim TY
Cancer Res Treat; 2016 Jul; 48(3):990-7. PubMed ID: 26790967
[TBL] [Abstract][Full Text] [Related]
8. [Severe Liver Injury Due to Sinusoidal Obstruction Syndrome Induced by Oxaliplatin in a Patient with Resectable Colorectal Liver Metastases].
Tominaga K; Kurumiya Y; Sekoguchi E; Kobayashi S; Kawai K; Kiriyama M
Gan To Kagaku Ryoho; 2018 Jun; 45(6):989-992. PubMed ID: 30026429
[TBL] [Abstract][Full Text] [Related]
9. [Tolerability of XELOX in postoperative adjuvant chemotherapy for colorectal cancer].
Matsuda C; Danno K; Miyazaki S; Fujitani K; Kubota M; Kawada J; Takagi M; Fukui A; Iwase K; Tanaka Y
Gan To Kagaku Ryoho; 2014 Jun; 41(6):743-7. PubMed ID: 25129086
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin toxicity presenting as a liver nodule - case report.
Alexandrino H; Oliveira D; Cipriano MA; Ferreira L; Tralhão JG; Castro E Sousa F
BMC Cancer; 2015 Apr; 15():247. PubMed ID: 25886004
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Noh SH; Park SR; Yang HK; Chung HC; Chung IJ; Kim SW; Kim HH; Choi JH; Kim HK; Yu W; Lee JI; Shin DB; Ji J; Chen JS; Lim Y; Ha S; Bang YJ;
Lancet Oncol; 2014 Nov; 15(12):1389-96. PubMed ID: 25439693
[TBL] [Abstract][Full Text] [Related]
12. Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection.
Duwe G; Knitter S; Pesthy S; Beierle AS; Bahra M; Schmelzle M; Schmuck RB; Lohneis P; Raschzok N; Öllinger R; Sinn M; Struecker B; Sauer IM; Pratschke J; Andreou A
Eur J Surg Oncol; 2017 Sep; 43(9):1668-1681. PubMed ID: 28599872
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Sinusoidal Obstruction Syndrome in Gastric Cancer Patients Receiving S-1/oxaliplatin
Kim EJ; Kim M; Seo S; Kim MJ; Kim MJ; Park SR
Anticancer Res; 2021 Jan; 41(1):391-402. PubMed ID: 33419836
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab improves splenomegaly and decreases production of hyaluronic acid after L-OHP based chemotherapy.
Arakawa Y; Shimada M; Utsunomiya T; Imura S; Morine Y; Ikemoto T; Hanaoka J; Kanamoto M; Iwahashi S; Saito Y; Yamada S; Asanoma M; Takasu C; Bando Y
Anticancer Res; 2014 Apr; 34(4):1953-8. PubMed ID: 24692731
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model.
Robinson SM; Mann J; Vasilaki A; Mathers J; Burt AD; Oakley F; White SA; Mann DA
J Hepatol; 2013 Aug; 59(2):318-26. PubMed ID: 23624001
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine and oxaliplatin (XELOX) is safe and effective in patients with advanced gastric cancer.
Quek R; Lim WT; Foo KF; Koo WH; A-Manaf A; Toh HC
Acta Oncol; 2007; 46(7):1032-4. PubMed ID: 17917832
[No Abstract] [Full Text] [Related]
17. Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study.
Fuse N; Bando H; Chin K; Ito S; Yoshikawa T; Tsuburaya A; Terashima M; Kawashima Y; Fukunaga T; Gotoh M; Emi Y; Yoshida K; Oki E; Takahashi S; Kuriki H; Sato K; Sasako M
Gastric Cancer; 2017 Mar; 20(2):332-340. PubMed ID: 26956689
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L
J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
Klinger M; Eipeldauer S; Hacker S; Herberger B; Tamandl D; Dorfmeister M; Koelblinger C; Gruenberger B; Gruenberger T
Eur J Surg Oncol; 2009 May; 35(5):515-20. PubMed ID: 19200687
[TBL] [Abstract][Full Text] [Related]
20. Hepatic Parenchymal Heterogeneity as a Marker for Oxaliplatin-Induced Sinusoidal Obstruction Syndrome: Correlation With Treatment Response of Colorectal Cancer Liver Metastases.
Han NY; Park BJ; Yang KS; Kim MJ; Sung DJ; Sim KC; Cho SB
AJR Am J Roentgenol; 2017 Nov; 209(5):1039-1045. PubMed ID: 28813196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
